Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19.
COVID-19
cytokines
melatonin
melatonin receptors
outpatient
Journal
Journal of pineal research
ISSN: 1600-079X
Titre abrégé: J Pineal Res
Pays: England
ID NLM: 8504412
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
12
03
2021
received:
15
01
2021
accepted:
13
03
2021
pubmed:
25
3
2021
medline:
29
7
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Data indicate that controlling inflammatory responses to COVID-19 may be as important as antiviral therapies or could be an important adjunctive approach. Melatonin possesses anti-inflammation, antioxidation, and immune-enhancing features directly and/or indirectly through its own receptor signaling and is therefore well suited to reduce the severity of COVID-19. Studies have proposed that melatonin regulates COVID-19-associated proteins directly through regulation of molecules such as calmodulin (CALM) 1 and CALM 2, calreticulin (CalR), or myeloperoxidase (MPO) and/or indirectly through actions on GPCR (eg, MTNR1A, MTNR1B) and nuclear (eg, RORα, RORβ) melatonin receptor signaling. However, the exact mechanism(s) and doses by which melatonin reduces the severity of COVID-19 is still open for debate, warranting the need for further testing of melatonin in placebo-controlled randomized clinical trials for COVID-19.
Identifiants
pubmed: 33759236
doi: 10.1111/jpi.12732
pmc: PMC8250125
mid: NIHMS1705618
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Receptors, Melatonin
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12732Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001413
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129649
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Annu Rev Pharmacol Toxicol. 2016;56:361-83
pubmed: 26514204
PLoS One. 2020 Oct 2;15(10):e0240149
pubmed: 33006999
Biochem Pharmacol. 2003 Mar 1;65(5):731-9
pubmed: 12628486
J Pineal Res. 2014 May;56(4):427-38
pubmed: 24650045
Clin Pharmacol Ther. 1995 May;57(5):552-8
pubmed: 7768078
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
Front Endocrinol (Lausanne). 2019 Mar 01;10:87
pubmed: 30881340
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7997-E8006
pubmed: 28874589
Sci Rep. 2018 Oct 22;8(1):15579
pubmed: 30349079
PLoS Biol. 2020 Nov 6;18(11):e3000970
pubmed: 33156843
J Pineal Res. 2021 Aug;71(1):e12732
pubmed: 33759236
FASEB J. 1998 Jun;12(9):685-93
pubmed: 9619447
Sleep Med Rev. 2005 Feb;9(1):25-39
pubmed: 15649736
Endocrine. 2005 Jul;27(2):189-200
pubmed: 16217132
J Pineal Res. 2013 Apr;54(3):313-21
pubmed: 23110416
Diseases. 2020 Nov 26;8(4):
pubmed: 33256258
Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1824-8
pubmed: 8127888
Clin Drug Investig. 2016 Mar;36(3):169-75
pubmed: 26692007
Sleep Med. 2007 Dec;8 Suppl 3:34-42
pubmed: 18032103